Matt Hoffman

The use of electroconvulsive therapy in patients with bipolar depression resulted in higher remission rates while showing similar response rates to unipolar major depression.

The algorithm is intended to help prevent mistakes caused by a slew of issues, from burnout at the end of a long day to overconfidence in decision-making.

Andexanet alfa showed a median decrease in anti-Factor Xa activity from baseline of 97% for those on rivaroxaban and 92% for those on apixaban.

An assessment of the burden felt by caregivers of patients with cognitive impairment sought to identify a relationship between the level of burden and the level of impairment.

All told, 68% of the group receiving a full dose of MDMA no longer qualified for a PTSD diagnosis compared to 29% in the active-placebo control group.

FusionVu allows for the fastest and simplest real-time targeting of prostate biopsies while also providing the highest resolution in real-time guidance for them, according to Exact Imaging.

The BLA was originally accepted by the FDA for review in September 2017, with the product intended to be used for the treatment of immunological conditions such as rheumatoid arthritis, as well as blood cancers.

The new indication will allow wearers to use the contacts for up to 6 nights and 7 days continuously.

The technology can be used with both steam and vaporized hydrogen peroxide, simultaneously in any incubation well.

The prevalence of ASD among 8-year-old children has increased 0.2%, including increases in the black and Hispanic communities according to recent CDC data.

The American Academy of Family Physicians is seeking to fight physician burnout with newly announced resources.

A favorable overall response to treatment was comparable between the IMI/REL (71.4%) and the colistin plus IMI (70%) arms.

The therapy met all co-primary and ranked secondary endpoints in the 4 trials without displaying any new safety signals, according to AbbVie.

Data from a duo of poster presentations showed icosapent ethyl reduced potentially atherogenic lipid and inflammatory markers in statin-treated patients with reduced kidney function and high triglycerides.

The expanded indication was granted based on data from the IMPACT trial, in which it showed superiority to FF/VI and UMEC/VI.

Prolonged exposure to the over the counter medicine was associated with a 30% increase in the relative risk of ADHD and a 20% increase in the relative risk of ASD.

In total, 35% of all HCPs polled responded that the inhalation device is “highly important” when determining medication for a newly diagnosed, stable patient with COPD.

These devices provide additional treatment options for an often-underdiagnosed condition that impacts 12% to 20% of Americans older than 60.

Study findings indicated that the BRUKER MALDI Biotyper CA system was able to identify the pathogen 100% of the time.

Two recent studies on surgical attrition have unveiled the factors that impact dropout rates and timing, highlighting the need for better guidance and early intervention for medical students entering surgical training.

As the number of primary care physicians shrinks, nurse practitioners have a unique opportunity to fill gaps in care.

While its safety profile was lessened, celecoxib, in comparison with naproxen and ibuprofen, remained favorable when taken with aspirin.

Data revealed a response rate of 29% for those on the therapy compared to 2% with placebo, with median platelet counts at 24 weeks of 95,000/µL in the SR group, 49,000/µL in the IR group, and 20,500/µL in the non-responders.

SGLT-2 inhibitors and GLP-1 agonists were associated with 1% and 0.6% reductions in all-cause mortality, respectively.

The therapy, when used prophylactically either weekly or biweekly, showed a statistically significant reduction in treated bleeds in comparison to no prophylaxis.

In 90 patients that received idarucizumab in the RE-VERSE AD phase 3 trial, the median maximum percentage reversal was 100%.

The likelihood that a patient would receive a new opioid prescription was higher for at-risk patients and remained true even after adjusting for demographic characteristics, comorbidities, and diagnoses associated with pain.

The benefit for patients without diabetes was +0.3 ml/min/1.73 m2 per year and for those with concurrent diabetes, the benefit was doubled to +.06 ml/min/1.73 m2.

The NDA acceptance comes just days after the FDA issued a Refusal to File letter to Alkermes for its investigational MDD therapy.

While pre-pregnancy blood pressure can impact pregnancy outcomes, targeted lifestyle interventions could be utilized to favorably impact reproductive health.